癌症相关双膦酸盐性骨坏死（BON）的系统综述。
A systematic review of bisphosphonate osteonecrosis (BON) in cancer.
机构信息
Department of Biologic and Diagnostic Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
出版信息
Support Care Cancer. 2010 Aug;18(8):1099-106. doi: 10.1007/s00520-010-0882-1. Epub 2010 Apr 22.
PURPOSE
This systematic review aims to examine the prevalence of bisphosphonate osteonecrosis (BON) in the cancer population, prevention and treatment protocols, and quality of life issues.
METHODS
A search of MEDLINE/PubMed and EMBASE form October 2003 to December 31, 2008 was conducted with the objective of identifying publications that contained original data regarding BON.
RESULTS
A total of 28 publications fulfilled inclusion criteria, but only 22 were used for prevalence analysis. No randomized controlled clinical trials, meta-analysis, or quality of life papers were found that contained information regarding either prevalence or treatment protocols for the management of BON. The overall weighted prevalence of BON included a sample of 39,124 patients with a mean weighted prevalence of 6.1%. The weighted prevalence was 13.3% for studies with documented follow-up with a sample size of 927 individuals. The weighted prevalence in studies with undocumented follow-up was 0.7% in a sample of 8,829 chart reviews. Epidemiological studies evaluated a total of 29,368 individual records, and the weighted BON prevalence was 1.2%.
CONCLUSIONS
High-quality studies are needed to accurately characterize the prevalence of BON, and to determine effective treatment protocols.
目的
本系统评价旨在调查癌症患者中双膦酸盐相关性骨坏死（BON）的流行率、预防和治疗方案以及生活质量问题。
方法
检索 MEDLINE/PubMed 和 EMBASE 数据库，检索时间为 2003 年 10 月至 2008 年 12 月 31 日，目的是确定包含有关 BON 的原始数据的出版物。
结果
共有 28 篇文献符合纳入标准，但仅有 22 篇用于流行率分析。未发现包含 BON 流行率或治疗方案管理信息的随机对照临床试验、荟萃分析或生活质量研究。包含 39124 例患者的样本的 BON 总体加权流行率为 6.1%。有随访记录的研究样本为 927 例，加权流行率为 13.3%。无随访记录的研究样本为 8829 例，加权流行率为 0.7%。在评估了 29368 例个体记录的流行病学研究中，BON 的加权流行率为 1.2%。
结论
需要高质量的研究来准确描述 BON 的流行率，并确定有效的治疗方案。
Zotero 插件